MoonLake Immunotherapeutics

Helix Acquisition Corp (Nasdaq: HLXA) was a healthcare-focused special purpose acquisition company that completed its IPO in 2021 with a stated mandate to target the biopharmaceutical sector. The SPAC executed a business combination with MoonLake Immunotherapeutics, a clinical-stage company developing nanobody-based therapies that target IL-17A and IL-17F inflammatory pathways for conditions including psoriatic arthritis and hidradenitis suppurativa. The April 11, 2022 8-K filing reflects activity tied to the closing of that transaction, after which the combined entity continued operations under the MoonLake Immunotherapeutics name on Nasdaq. Sign up on SpacDesk for the full HLXA filing history, deal timeline, and real-time analytics across hundreds of SPAC transactions.